CK Aspire are delighted to have been named a finalist in the EyeforPharma Most Valuable Patient Initiative category in collaboration with GSK on the Salford Lung Study.
The finalists of this award are innovative projects designed to deliver tangible patient improvements both in the long and short term. Demonstrating real understanding for the patient requirements prior to implementation, these finalists have been managed to an outstanding level and have made an exceptionally positive impact on their intended customer.
The study, was the world’s first digitally enhanced Randomised Controlled Trial and adopted some pioneering approaches to gain access too hard to reach audiences. A range of strategies were employed to ensure the data submitted included a broad and inclusive population.
To have been shortlisted alongside some highly credible projects and impressive organisations is a true testament to the innovation and commitment of the staff delivering this clinical trial.
For more information on the SLS project or any of our services click here to contact us